Gelsolin amyloidosis: Genetics, biochemistry, pathology and possible strategies for therapeutic intervention

Critical Reviews in Biochemistry and Molecular Biology

Volumn 47, Issue 3, 2012, Pages 282-296

  Solomon, James P ^a   Page, Lesley J ^a   Balch, William E ^a   Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Aberrant proteolysis; Amyloidogenesis; Calcium binding; Familial amyloidosis of Finnish type; Furin; Gelsolin amyloid disease

Indexed keywords

FURIN; GELSOLIN; METALLOPROTEINASE;

BIOCHEMISTRY; CALCIUM BINDING; CARBOXY TERMINAL SEQUENCE; CLINICAL FEATURE; EXTRACELLULAR SPACE; FAMILIAL AMYLOIDOSIS; GELSOLIN AMYLOIDOSIS; GENETICS; GOLGI COMPLEX; HUMAN; IN VITRO STUDY; MUTATION; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; REVIEW;

AMYLOID; AMYLOIDOSIS, FAMILIAL; ANIMALS; BENZOXAZOLES; FURIN; GELSOLIN; GOLGI APPARATUS; HUMANS; MICE; PEPTIDE FRAGMENTS; POINT MUTATION; PROTEIN FOLDING; PROTEOLYSIS;

EID: 84860128609     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2012.661401     Document Type: Review

References (145)

1. Ardalan MR, Shoja MM, Kiuru-Enari S. 2007. Amyloidosis-related nephrotic syndrome due to a G654A gelsolin mutation: the first report from the Middle East. Nephrol Dial Transplant 22: 272-275. (Pubitemid 46050357)
2. Arumugam TV, Cheng YL, Choi Y, Choi YH, Yang S, Yun YK, Park JS, Yang DK, Thundyil J, Gelderblom M, Karamyan VT, Tang SC, Chan SL, Magnus T, Sobey CG, Jo DG. 2011. Evidence that γ-secretase-mediated Notch signaling induces neuronal cell death via the nuclear factor-κB-Bcl-2-interacting mediator of cell death pathway in ischemic stroke. Mol Pharmacol 80: 23-31.
3. Ashish Paine, MS, Perryman PB, Yang L, Yin HL, Krueger JK. 2007. Global structure changes associated with Ca2+ activation of fulllength human plasma gelsolin. J Biol Chem 282: 25884-25892. (Pubitemid 47372805)
4. Balch WE, Morimoto RI, Dillin A, Kelly JW. 2008. Adapting proteostasis for disease intervention. Science 319: 916-919. (Pubitemid 351263754)
5. Baures PW, Peterson SA, Kelly JW. 1998. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem 6: 1389-1401. (Pubitemid 28398970)
6. Baures PW, Oza VB, Peterson SA, Kelly JW. 1999. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg Med Chem 7: 1339-1347. (Pubitemid 29292374)
7. Bieschke J, Zhang Q, Bosco DA, Lerner RA, Powers ET, Wentworth P Jr, Kelly JW. 2006. Small molecule oxidation products trigger disease-associated protein misfolding. Acc Chem Res 39: 611-619.
8. Bieschke J, Zhang Q, Powers ET, Lerner RA, Kelly JW. 2005. Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a twostep mechanism, eliminating the requirement for nucleation. Biochemistry 44: 4977-4983. (Pubitemid 40471214)
9. Blake CC, Serpell LC, Sunde M, Sandgren O, Lundgren E. 1996. A molecular model of the amyloid fibril. Ciba Found Symp 199: 6-15; discussion 15.
10. Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, Hawkins PN, Dobson CM, Radford SE, Blake CC, Pepys MB. 1997. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385: 787-793. (Pubitemid 27106061)
11. Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P Jr, Lerner RA, Kelly JW. 2006. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α-synuclein fibrilization. Nat Chem Biol 2: 249-253.
12. Bourgault S, Solomon JP, Reixach N, Kelly JW. 2011. Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry 50: 1001-1015.
13. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511. (Pubitemid 34288846)
14. Bucki R, Byfield FJ, Kulakowska A, McCormick ME, Drozdowski W, Namiot Z, Hartung T, Janmey PA. 2008a. Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. J Immunol 181: 4936-4944.
15. Bucki R, Kulakowska A, Byfield FJ, Zendzian-Piotrowska M, Baranowski M, Marzec M, Winer JP, Ciccarelli NJ, Górski J, Drozdowski W, Bittman R, Janmey PA. 2010. Plasma gelsolin modulates cellular response to sphingosine 1-phosphate. Am J Physiol, Cell Physiol 299: C1516-C1523.
16. Bucki R, Levental I, Kulakowska A, Janmey PA. 2008b. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci 9: 541-551.
17. Burtnick LD, Koepf EK, Grimes J, Jones EY, Stuart DI, McLaughlin PJ, Robinson RC. 1997. The crystal structure of plasma gelsolin: implications for actin severing, capping, and nucleation. Cell 90: 661-670. (Pubitemid 27357958)
18. Carrwik C, Stenevi U. 2009. Lattice corneal dystrophy, gelsolin type (Meretoja's syndrome). Acta Ophthalmol 87: 813-819.
19. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destée A. 2004. α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169. (Pubitemid 39296604)
20. Chastan N, Baert-Desurmont S, Saugier-Veber P, Dérumeaux G, Cabot A, Frébourg T, Hannequin D. 2006. Cardiac conduction alterations in a French family with amyloidosis of the Finnish type with the p.Asp187Tyr mutation in the GSN gene. Muscle Nerve 33: 113-119. (Pubitemid 43062993)
21. Chauhan V, Ji L, Chauhan A. 2008. Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease. Biogerontology 9: 381-389.
22. Chauhan VP, Ray I, Chauhan A, Wisniewski HM. 1999. Binding of gelsolin, a secretory protein, to amyloid β-protein. Biochem Biophys Res Commun 258: 241-246. (Pubitemid 29287035)
23. Chen CD, Huff ME, Matteson J, Page L, Phillips R, Kelly JW, Balch WE. 2001. Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J 20: 6277-6287. (Pubitemid 33078701)
24. Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. 2003. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424: 805-808. (Pubitemid 37021713)
25. Choe H, Burtnick LD, Mejillano M, Yin HL, Robinson RC, Choe S. 2002. The calcium activation of gelsolin: insights from the 3A structure of the G4-G6/actin complex. J Mol Biol 324: 691-702. (Pubitemid 36044107)
26. Choo DW, Schneider JP, Graciani NR, Kelly JW. 1996. Nucleated antiparallel OE≤-sheet that folds and undergoes self-assembly: a template promoted folding strategy toward controlled molecular architectures. Macromolecules 29: 355-366. (Pubitemid 126548685)
27. Coelho T, Maia L, Da Silva AM, Cruz MW, Plante-Bordeneuve V, Lozeron P, Suhr OB, Campistol J, Conceicao I, Schmidt H, Trigo P, Packman J, Grogan DR. 2011. A comprehensive evaluation of the disease-modifying effects of tafamidis in patients with transthyretin type familial amyloid polyneuropathy. Neurology 76: A111-A111.
28. Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, Adame A, Pham HM, Holzenberger M, Kelly JW, Masliah E, Dillin A. 2009. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139: 1157-1169.
29. Cohen FE, Kelly JW. 2003. Therapeutic approaches to proteinmisfolding diseases. Nature 426: 905-909.
30. Conceição I, Sales-Luis ML, De Carvalho M, Evangelista T, Fernandes R, Paunio T, Kangas H, Coutinho P, Neves C, Saraiva MJ. 2003. Gelsolin-related familial amyloidosis, Finnish type, in a Portuguese family: clinical and neurophysiological studies. Muscle Nerve 28: 715-721. (Pubitemid 37484834)
31. Contégal F, Bidot S, Thauvin C, Lévèue L, Soichot P, Gras P, Moreau T, Giroud M. 2006. Finnish amyloid polyneuropathy in a French patient. Rev Neurol (Paris) 162: 997-1001. (Pubitemid 44495493)
32. De La Chapelle A, Tolvanen R, Boysen G, Santavy J, Bleekerwagemakers L, Maury CPJ, Kere J. 1992. Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. Nat Genet 2: 157-160.
33. Dobson CM. 2003. Protein folding and misfolding. Nature 426: 884-890. (Pubitemid 38056880)
34. Engel WK, Askanas V. 2006. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 66: S20-S29. (Pubitemid 43739980)
35. Falzone TL, Gunawardena S, McCleary D, Reis GF, Goldstein LS. 2010. Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies. Hum Mol Genet 19: 4399-4408.
36. Fändrich M, Fletcher MA, Dobson CM. 2001. Amyloid fibrils from muscle myoglobin. Nature 410: 165-166.
37. Felix EPV, Jung LS, Carvalho GS, Oliveira ASB. 2008. Corneal lattic dystrophy type II: Familial amyloid neuropathy type IV (gelsolin amyloidosis). Einstein 6: 505-506.
38. Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L. 2004. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 22: 1302-1306. (Pubitemid 39336784)
39. Ferrone F. 1999. Analysis of protein aggregation kinetics. Amyloid, Prions, and Other Protein Aggregates San Diego: Academic Press Inc.
40. Gandhi NS, Mancera RL. 2008. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 72: 455-482.
41. Green NS, Palaninathan SK, Sacchettini JC, Kelly JW. 2003. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J Am Chem Soc 125: 13404-13414. (Pubitemid 37352125)
42. Güntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL, Ward MA, Lovestone S. 2010. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis 21: 585-596.
43. Haltia M, Prelli F, Ghiso J, Kiuru S, Somer H, Palo J, Frangione B. 1990. Amyloid protein in familial amyloidosis (Finnish type) is homologous to gelsolin, an actin-binding protein. Biochem Biophys Res Commun 167: 927-932. (Pubitemid 20113270)
44. Hammarström P, Sekijima Y, White JT, Wiseman RL, Lim A, Costello CE, Altland K, Garzuly F, Budka H, Kelly JW. 2003a. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry 42: 6656-6663. (Pubitemid 36666106)
45. Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW. 2002. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 99 Suppl 4: 16427-16432. (Pubitemid 35470989)
46. Hammarström P, Schneider F, Kelly JW. 2001. Trans-suppression of misfolding in an amyloid disease. Science 293: 2459-2462. (Pubitemid 32917328)
47. Hammarström P, Wiseman RL, Powers ET, Kelly JW. 2003b. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 299: 713-716. (Pubitemid 36159487)
48. Hartl FU, Bracher A, Hayer-Hartl M. 2011. Molecular chaperones in protein folding and proteostasis. Nature 475: 324-332.
49. Her LS, Goldstein LS. 2008. Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci 28: 13662-13672.
50. Hirko AC, Meyer EM, King MA, Hughes JA. 2007. Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Mol Ther 15: 1623-1629. (Pubitemid 47289005)
51. Huerva V, Velasco A, Sánchez MC, Mateo AJ, Matías-Guiu X. 2007. Lattice corneal dystrophy type II: clinical, pathologic, and molecular study in a Spanish family. Eur J Ophthalmol 17: 424-429. (Pubitemid 47056302)
52. Huff ME, Balch WE, Kelly JW. 2003a. Pathological and functional amyloid formation orchestrated by the secretory pathway. Curr Opin Struct Biol 13: 674-682. (Pubitemid 37522142)
53. Huff ME, Page LJ, Balch WE, Kelly JW. 2003b. Gelsolin domain 2 Ca2+ affinity determines susceptibility to furin proteolysis and familial amyloidosis of Finnish type. J Mol Biol 334: 119-127. (Pubitemid 37330104)
54. Hurshman Babbes AR, Powers ET, Kelly JW. 2008. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 47: 6969-6984. (Pubitemid 351898951)
55. Ibáñez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, Agid Y, Dürr A, Brice A. 2004. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364: 1169-1171. (Pubitemid 39296605)
56. Ikeda M, Mizushima K, Fujita Y, Watanabe M, Sasaki A, Makioka K, Enoki M, Nakamura M, Otani T, Takatama M, Okamoto K. 2007. Familial amyloid polyneuropathy (Finnish type) in a Japanese family: clinical features and immunocytochemical studies. J Neurol Sci 252: 4-8. (Pubitemid 44909180)
57. Imbimbo BP, Giardina GA. 2011. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem 11: 1555-1570.
58. Ji L, Chauhan A, Chauhan V. 2008. Cytoplasmic gelsolin in pheochromocytoma-12 cells forms a complex with amyloid betaprotein. Neuroreport 19: 463-466. (Pubitemid 351301606)
59. Jiang X, Buxbaum JN, Kelly JW. 2001. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA 98: 14943-14948. (Pubitemid 34013949)
60. Jiao GS, Cregar L, Wang J, Millis SZ, Tang C, O'Malley S, Johnson AT, Sareth S, Larson J, Thomas G. 2006. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc Natl Acad Sci USA 103: 19707-19712. (Pubitemid 46037496)
61. Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. 2005. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 38: 911-921.
62. Kangas H, Paunio T, Kalkkinen N, Jalanko A, Peltonen L. 1996. In vitro expression analysis shows that the secretory form of gelsolin is the sole source of amyloid in gelsolin-related amyloidosis. Hum Mol Genet 5: 1237-1243. (Pubitemid 26335840)
63. Kangas H, Seidah NG, Paunio T. 2002. Role of proprotein convertases in the pathogenic processing of the amyloidosis-associated form of secretory gelsolin. Amyloid 9: 83-87. (Pubitemid 34787801)
64. Kazmirski SL, Isaacson RL, An C, Buckle A, Johnson CM, Daggett V, Fersht AR. 2002. Loss of a metal-binding site in gelsolin leads to familial amyloidosis-Finnish type. Nat Struct Biol 9: 112-116. (Pubitemid 34132412)
65. Kelly JW. 1996. Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 6: 11-17. (Pubitemid 26073939)
66. Kelly JW. 1998. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 8: 101-106. (Pubitemid 28107921)
67. Khaitlina S, Hinssen H. 2002. Ca-dependent binding of actin to gelsolin. FEBS Lett 521: 14-18. (Pubitemid 34628449)
68. Kiuru-Enari S, Keski-Oja J, Haltia M. 2005. Cutis laxa in hereditary gelsolin amyloidosis. Br J Dermatol 152: 250-257. (Pubitemid 40343594)
69. Kiuru-Enari S, Somer H, Seppäläinen AM, Notkola IL, Haltia M. 2002. Neuromuscular pathology in hereditary gelsolin amyloidosis. J Neuropathol Exp Neurol 61: 565-571. (Pubitemid 34603005)
70. Kiuru S. 1998. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 5: 55-66. (Pubitemid 128691218)
71. Kiuru S, Matikainen E, Kupari M, Haltia M, Palo J. 1994. Autonomic nervous system and cardiac involvement in familial amyloidosis, Finnish type (FAF). J Neurol Sci 126: 40-48. (Pubitemid 24305257)
72. Kivelä T, Tarkkanen A, Frangione B, Ghiso J, Haltia M. 1994. Ocular amyloid deposition in familial amyloidosis, Finnish: an analysis of native and variant gelsolin in Meretoja's syndrome. Invest Ophthalmol Vis Sci 35: 3759-3769. (Pubitemid 24337989)
73. Kolstoe SE, Mangione PP, Bellotti V, Taylor GW, Tennent GA, Deroo S, Morrison AJ, Cobb AJ, Coyne A, McCammon MG, Warner TD, Mitchell J, Gill R, Smith MD, Ley SV, Robinson CV, Wood SP, Pepys MB. 2010. Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci USA 107: 20483-20488.
74. Kwiatkowski DJ, Mehl R, Izumo S, Nadal-Ginard B, Yin HL. 1988. Muscle is the major source of plasma gelsolin. J Biol Chem 263: 8239-8243.
75. Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Colten HR, Yin HL. 1986. Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature 323: 455-458. (Pubitemid 16026275)
76. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. 1998. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453.
77. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. 2002. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418: 291. (Pubitemid 34790672)
78. Lee J, Culyba EK, Powers ET, Kelly JW. 2011. Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol 7: 602-609.
79. Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. 2007. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 35: 849-855. (Pubitemid 46407801)
80. Liepina I, Czaplewski C, Janmey P, Liwo A. 2003. Molecular dynamics study of a gelsolin-derived peptide binding to a lipid bilayer containing phosphatidylinositol 4,5-bisphosphate. Biopolymers 71: 49-70. (Pubitemid 36548117)
81. Lomakin A, Teplow DB, Kirschner DA, Benedek GB. 1997. Kinetic theory of fibrillogenesis of amyloid β-protein. Proc Natl Acad Sci USA 94: 7942-7947. (Pubitemid 27343754)
82. Lueck A, Yin HL, Kwiatkowski DJ, Allen PG. 2000. Calcium regulation of gelsolin and adseverin: a natural test of the helix latch hypothesis. Biochemistry 39: 5274-5279. (Pubitemid 30257065)
83. Lüttmann RJ, Teismann I, Husstedt IW, Ringelstein EB, Kuhlenbäumer G. 2010. Hereditary amyloidosis of the Finnish type in a German family: clinical and electrophysiological presentation. Muscle Nerve 41: 679-684.
84. Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, Schubert D, Riek R. 2005. 3D structure of Alzheimer's amyloid-β(1-42) fibrils. Proc Natl Acad Sci USA 102: 17342-17347.
85. Mahalka AK, Maury CP, Kinnunen PK. 2011. 1-Palmitoyl-2-(9'-oxononanoyl)- sn-glycero-3-phosphocholine, an oxidized phospholipid, accelerates Finnish type familial gelsolin amyloidosis in vitro. Biochemistry 50: 4877-4889.
86. Makioka K, Ikeda M, Ikeda Y, Nakasone A, Osawa T, Sasaki A, Otani T, Arai M, Okamoto K. 2010. Familial amyloid polyneuropathy (Finnish type) presenting multiple cranial nerve deficits with carpal tunnel syndrome and orthostatic hypotension. Neurol Res 32: 472-475.
87. Maury CP. 1991. Gelsolin-related amyloidosis. Identification of the amyloid protein in Finnish hereditary amyloidosis as a fragment of variant gelsolin. J Clin Invest 87: 1195-1199.
88. Maury CP. 1993. Homozygous familial amyloidosis, Finnish type: demonstration of glomerular gelsolin-derived amyloid and nonamyloid tubular gelsolin. Clin Nephrol 40: 53-56. (Pubitemid 23221734)
89. Maury CP, Nurmiaho-Lassila EL, Rossi H. 1994. Amyloid fibril formation in gelsolin-derived amyloidosis. Definition of the amyloidogenic region and evidence of accelerated amyloid formation of mutant Asn-187 and Tyr-187 gelsolin peptides. Lab Invest 70: 558-564. (Pubitemid 24185027)
90. Meretoja J. 1969. Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. A previously unrecognized heritable syndrome. Ann Clin Res 1: 314-324.
91. Meretoja J. 1973. Genetic aspects of familial amyloidosis with corneal lattice dystrophy and cranial neuropathy. Clin Genet 4: 173-185.
92. Miller SR, Sekijima Y, Kelly JW. 2004. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 84: 545-552. (Pubitemid 38858463)
93. Nag S, Ma Q, Wang H, Chumnarnsilpa S, Lee WL, Larsson M, Kannan B, Hernandez-Valladares M, Burtnick LD, Robinson RC. 2009. Ca2+ binding by domain 2 plays a critical role in the activation and stabilization of gelsolin. Proc Natl Acad Sci USA 106: 13713-13718.
94. Nelson R, Sawaya MR, Balbirnie M, Madsen AØ, Riekel C, Grothe R, Eisenberg D. 2005. Structure of the cross-β spine of amyloid-like fibrils. Nature 435: 773-778. (Pubitemid 40839722)
95. Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer-Hartl M, Hartl FU, Vabulas RM. 2011. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144: 67-78.
96. Ong DS, Mu TW, Palmer AE, Kelly JW. 2010. Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis. Nat Chem Biol 6: 424-432.
97. Oza VB, Smith C, Raman P, Koepf EK, Lashuel HA, Petrassi HM, Chiang KP, Powers ET, Sachettinni J, Kelly JW. 2002. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem 45: 321-332. (Pubitemid 34073451)
98. Page LJ, Huff ME, Kelly JW, Balch WE. 2004. Ca2+ binding protects against gelsolin amyloidosis. Biochem Biophys Res Commun 322: 1105-1110. (Pubitemid 39164639)
99. Page LJ, Suk JY, Bazhenova L, Fleming SM, Wood M, Jiang Y, Guo LT, Mizisin AP, Kisilevsky R, Shelton GD, Balch WE, Kelly JW. 2009. Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc Natl Acad Sci USA 106: 11125-11130.
100. Page LJ, Suk JY, Huff ME, Lim HJ, Venable J, Yates J, Kelly JW, Balch WE. 2005. Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. EMBO J 24: 4124-4132. (Pubitemid 41752881)
101. Park SM, Hwang IK, Kim SY, Lee SJ, Park KS, Lee ST. 2006. Characterization of plasma gelsolin as a substrate for matrix metalloproteinases. Proteomics 6: 1192-1199.
102. Paunio T, Kangas H, Kalkkinen N, Haltia M, Palo J, Peltonen L. 1994. Toward understanding the pathogenic mechanisms in gelsolinrelated amyloidosis: in vitro expression reveals an abnormal gelsolin fragment. Hum Mol Genet 3: 2223-2229.
103. Pepys MB. 2006. Amyloidosis. Annu Rev Med 57: 223-241. (Pubitemid 43261989)
104. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R. 2002. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 99: 16742-16747. (Pubitemid 36034043)
105. Petrassi HM, Klabunde T, Sacchettini J, Kelly JW. 2000. Structurebased design of n-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J Am Chem So 122: 2178-2192. (Pubitemid 30164628)
106. Pihlamaa T, Rautio J, Kiuru-Enari S, Suominen S. 2011. Gelsolin amyloidosis as a cause of early aging and progressive bilateral facial paralysis. Plast Reconstr Surg 127: 2342-2351.
107. Planté-Bordeneuve V, Said G. 2011. Familial amyloid polyneuropathy. Lancet Neurol 10: 1086-1097.
108. Powers ET, Powers DL. 2008. Mechanisms of protein fibril formation: nucleated polymerization with competing off-pathway aggregation. Biophys J 94: 379-391.
109. Ratnaswamy G, Huff ME, Su AI, Rion S, Kelly JW. 2001. Destabilization of Ca2+-free gelsolin may not be responsible for proteolysis in familial amyloidosis of Finnish type. Proc Natl Acad Sci USA 98: 2334-2339. (Pubitemid 32209483)
110. Ratnaswamy G, Koepf E, Bekele H, Yin H, Kelly JW. 1999. The amyloidogenicity of gelsolin is controlled by proteolysis and pH. Chem Biol 6: 293-304. (Pubitemid 29363180)
111. Ray I, Chauhan A, Wegiel J, Chauhan VP. 2000. Gelsolin inhibits the fibrillization of amyloid β-protein, and also defibrillizes its preformed fibrils. Brain Res 853: 344-351. (Pubitemid 30035235)
112. Robinson RC, Mejillano M, Le VP, Burtnick LD, Yin HL, Choe S. 1999. Domain movement in gelsolin: a calcium-activated switch. Science 286: 1939-1942. (Pubitemid 129515899)
113. Rosenberg ME, Tervo TM, Gallar J, Acosta MC, Müller LJ, Moilanen JA, Tarkkanen AH, Vesaluoma MH. 2001. Corneal morphology and sensitivity in lattice dystrophy type II (familial amyloidosis, Finnish type). Invest Ophthalmol Vis Sci 42: 634-641. (Pubitemid 32206902)
114. Roustan C, Ferjani I, Maciver SK, Fattoum A, Rebière B, Benyamin Y. 2007. Calcium-induced conformational changes in the aminoterminal half of gelsolin. FEBS Lett 581: 681-686. (Pubitemid 46216292)
115. Sabaté R, Estelrich J. 2005. Evidence of the existence of micelles in the fibrillogenesis of beta-amyloid peptide. J Phys Chem B 109: 11027-11032. (Pubitemid 40844540)
116. Sambamurti K, Greig NH, Utsuki T, Barnwell EL, Sharma E, Mazell C, Bhat NR, Kindy MS, Lahiri DK, Pappolla MA. 2011. Targets for AD treatment: conflicting messages from γ-secretase inhibitors. J Neurochem 117: 359-374.
117. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJ, McFarlane HT, Madsen AØ, Riekel C, Eisenberg D. 2007. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447: 453-457. (Pubitemid 46816731)
118. Schor NF. 2011. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 69: 237-239.
119. Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, Kelly JW. 2005. The biological and chemical basis for tissue-selective amyloid disease. Cell 121: 73-85.
120. Selkoe DJ. 2003. Folding proteins in fatal ways. Nature 426: 900-904. (Pubitemid 38056883)
121. Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, Serpell L, Arnsdorf MF, Lindquist SL. 2000. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289: 1317-1321. (Pubitemid 30656041)
122. Shah SB, Nolan R, Davis E, Stokin GB, Niesman I, Canto I, Glabe C, Goldstein LS. 2009. Examination of potential mechanisms of amyloid-induced defects in neuronal transport. Neurobiol Dis 36: 11-25.
123. Shewmaker F, Kryndushkin D, Chen B, Tycko R, Wickner RB. 2009. Two prion variants of Sup35p have in-register parallel beta-sheet structures, independent of hydration. Biochemistry 48: 5074-5082.
124. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. α-Synuclein locus triplication causes Parkinson's disease. Science 302: 841. (Pubitemid 37339619)
125. Snow AD, Willmer J, Kisilevsky R. 1987. Sulfated glycosaminoglycans: a common constituent of all amyloids Lab Invest 56: 120-123. (Pubitemid 17011178)
126. Solomon JP, Bourgault S, Powers ET, Kelly JW. 2011. Heparin binds 8 kDa gelsolin cross-β-sheet oligomers and accelerates amyloidogenesis by hastening fibril extension. Biochemistry 50: 2486-2498.
127. Solomon JP, Yonemoto IT, Murray AN, Price JL, Powers ET, Balch WE, Kelly JW. 2009. The 8 and 5 kDa fragments of plasma gelsolin form amyloid fibrils by a nucleated polymerization mechanism, while the 68 kDa fragment is not amyloidogenic. Biochemistry 48: 11370-11380.
128. Stewart HS, Parveen R, Ridgway AE, Bonshek R, Black GC. 2000. Late onset lattice corneal dystrophy with systemic familial amyloidosis, amyloidosis V, in an English family. Br J Ophthalmol 84: 390-394. (Pubitemid 30255488)
129. Stokin GB, Goldstein LS. 2006. Axonal transport and Alzheimer's disease. Annu Rev Biochem 75: 607-627. (Pubitemid 44118045)
130. Suk JY, Zhang F, Balch WE, Linhardt RJ, Kelly JW. 2006. Heparin accelerates gelsolin amyloidogenesis. Biochemistry 45: 2234-2242. (Pubitemid 43271322)
131. Sun HQ, Yamamoto M, Mejillano M, Yin HL. 1999. Gelsolin, a multifunctional actin regulatory protein. J Biol Chem 274: 33179-33182. (Pubitemid 129511609)
132. Tanskanen M, Paetau A, Salonen O, Salmi T, Lamminen A, Lindsberg P, Somer H, Kiuru-Enari S. 2007. Severe ataxia with neuropathy in hereditary gelsolin amyloidosis: a case report. Amyloid 14: 89-95. (Pubitemid 46491167)
133. Tanzi RE, Bertram L. 2005. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120: 545-555. (Pubitemid 40269768)
134. Tycko R. 2003. Insights into the amyloid folding problem from solidstate NMR. Biochemistry 42: 3151-3159. (Pubitemid 36348623)
135. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. 2002. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539. (Pubitemid 34288854)
136. Walsh DM, Selkoe DJ. 2007. A β oligomers-a decade of discovery. J Neurochem 101: 1172-1184.
137. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. 2002. Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924: 133-140. (Pubitemid 34102301)
138. Wang H, Chumnarnsilpa S, Loonchanta A, Li Q, Kuan YM, Robine S, Larsson M, Mihalek I, Burtnick LD, Robinson RC. 2009. Helix straightening as an activation mechanism in the gelsolin superfamily of actin regulatory proteins. J Biol Chem 284: 21265-21269.
139. Wen D, Corina K, Chow EP, Miller S, Janmey PA, Pepinsky RB. 1996. The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 35: 9700-9709. (Pubitemid 26302982)
140. Wiseman RL, Powers ET, Buxbaum JN, Kelly JW, Balch WE. 2007. An adaptable standard for protein export from the endoplasmic reticulum. Cell 131: 809-821. (Pubitemid 350087203)
141. Witke W, Sharpe AH, Hartwig JH, Azuma T, Stossel TP, Kwiatkowski DJ. 1995. Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell 81: 41-51.
142. Yin HL, Kwiatkowski DJ, Mole JE, Cole FS. 1984. Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin. J Biol Chem 259: 5271-5276. (Pubitemid 14140637)
143. Yin HL, Stossel TP. 1979. Control of cytoplasmic actin gel-sol transformation by gelsolin, a calcium-dependent regulatory protein. Nature 281: 583-586. (Pubitemid 10242871)
144. Yu Z, Sawkar AR, Whalen LJ, Wong CH, Kelly JW. 2007. Isofagomine-and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem 50: 94-100. (Pubitemid 46105502)
145. Zhou A, Webb G, Zhu X, Steiner DF. 1999. Proteolytic processing in the secretory pathway. J Biol Chem 274: 20745-20748.